Alnylam

News Alnylam

• Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi patent

  Alnylam Pharmaceuticals, Inc. and Plant Bioscience Limited (PBL) announced  that they have entered into a licensing agreement.  PBL has granted Alnylam a world-wide, non-exclusive license to the Baulcombe patent (U.S. Patent No. 8,097,710) for use in the field of human therapeutics.  Financial terms more

• Alnylam Announces Extension of RNAi Therapeutics Collaboration with Novartis

  Alnylam Pharmaceuticals, Inc. announced that Novartis has elected to extend the company’s RNAi therapeutics collaboration for a fifth and final planned year, through October 2010. The landmark alliance was initiated in October 2005 and is focused on the discovery, development, and commercialization more

• IMM, Cenix and Alnylam Discover New Targets in Malaria Infection with RNAi Technology

  Alnylam Pharmaceuticals, Inc. and Cenix BioScience GmbH announced the publication of a new study in the journal PLoS Pathogens demonstrating in vitro and in vivo RNAi-mediated silencing of novel host factors involved in malaria infection. The work resulted from an ongoing malaria research program more

Market studies Alnylam

• Alnylam Pharmaceuticals, Inc – Product Pipeline Review – 2012

  Introduction Global Market Direct’s pharmaceuticals report, “Alnylam Pharmaceuticals, Inc - Product Pipeline Review - 2012” provides data on the Alnylam Pharmaceuticals, Inc’s research and development focus. The report includes information on current developmental pipeline, complete with latest up more

• Rosetta Genomics, Ltd. (ROSG) - Product Pipeline Analysis

  Rosetta Genomics, Ltd. (ROSG) - Product Pipeline Analysis Summary This report is a source for data, analysis and actionable intelligence on the Rosetta Genomics, Ltd. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, more

• World Biological Drugs Market 2011-2021

  Do you want to find market prospects for products and companies in the biological drugs industry? Our new report shows you biopharma revenue forecasts for 2011 to 2021. We provide original research, data and opinions to benefit your work now. What revenues will biopharmaceutical markets achieve fro more

Websites Alnylam